Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation

被引：0

作者：

Massarweh, S

Osborne, CK

Wakeling, AE

Schiff, R

机构：

[1] Baylor Coll Med, Houston, TX 77030 USA

[2] Astra Zeneca, Macclesfield, Cheshire, England

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S18 / S18

页数：1

共 50 条

[41] HER2 mutations detected by ctDNA in ER+/HER2-metastatic breast cancer patients: Incidence and impact on clinical outcomes
Medford, Arielle
Juric, Dejan
Niemierko, Andrzej
Malvarosa, Giuliana
Park, Hannah
Shellock, Maria
Spring, Laura
Moy, Beverly
Isakoff, Steven
Ellisen, Leif
Bardia, Aditya
CANCER RESEARCH, 2018, 78 (04)
[42] Analysis of estrogen receptor positive (ER+), progesterone receptor negative (PR-) phenotype and HER2 status in breast cancer (BC) patients
Mitrovic, Slobodanka
Stankovic, Vesna
Azanjac, Goran
Ninkovic, Srdan
VIRCHOWS ARCHIV, 2007, 451 (02) : 299 - 299
[43] Ovarian cancer expression of ER, PgR, EGFR, and Her2 in Irish women may predict for targeted therapies: A single institution experience
Quintyne, K. I.
Doyle, M.
Landers, R.
Cantwell, B. M.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[44] A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results.
Marcom, PK
Isaacs, C
Harris, L
Bryant, M
Kommareddy, A
Tao, Y
Mann, G
Ellis, MJ
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 27S - 27S
[45] Endoxifen exhibits potent in vitro and in vivo antitumor activity in ER+/HER2+breast cancer and tamoxifen refractory tumors
Reinicke, Kathryn E.
Hou, Xiaonan
Goetz, Matthew P.
Suman, Vera J.
Kuffel, Mary J.
Haluska, Paul
Reid, Joel M.
Ames, Matthew M.
CANCER RESEARCH, 2011, 71
[46] Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer
Yasuhiro Saito
Shiori Matsuda
Naomi Ohnishi
Keiko Endo
Sanae Ashitani
Maki Ohishi
Ayano Ueno
Masaru Tomita
Koji Ueda
Tomoyoshi Soga
Senthil K. Muthuswamy
Communications Biology, 5
[47] ASO Author Reflections: Considerations in the Debate on Sentinel Node Biopsy in Older Patients with ER+/Her2− Breast Cancer
Alice Chung
Annals of Surgical Oncology, 2024, 31 : 3198 - 3199
[48] Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay
Carsten Denkert
Ralf Kronenwett
Werner Schlake
Kerstin Bohmann
Roland Penzel
Karsten E. Weber
Heinz Höfler
Ulrich Lehmann
Peter Schirmacher
Katja Specht
Margaretha Rudas
Hans-Heinrich Kreipe
Peter Schraml
Gudrun Schlake
Zsuzsanna Bago-Horvath
Frank Tiecke
Zsuzsanna Varga
Holger Moch
Marcus Schmidt
Judith Prinzler
Dontscho Kerjaschki
Bruno Valentin Sinn
Berit Maria Müller
Martin Filipits
Christoph Petry
Manfred Dietel
Virchows Archiv, 2012, 460 : 251 - 259
[49] Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience
Mariangela Ciccarese
Alessandra Fabi
Luca Moscetti
Maria Elena Cazzaniga
Luciana Petrucelli
Rosachiara Forcignanò
Laura Isabella Lupo
Elisabetta De Matteis
Vincenzo Emanuele Chiuri
Giuseppe Cairo
Antonio Febbraro
Guido Giordano
Marianna Giampaglia
Domenico Bilancia
Nicla La Verde
Evaristo Maiello
Maria Morritti
Francesco Giotta
Vito Lorusso
Agnese Latorre
Claudio Scavelli
Sante Romito
Antonio Cusmai
Gennaro Palmiotti
Giammarco Surico
Breast Cancer Research and Treatment, 2017, 163 : 587 - 594
[50] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
Thaler, S.
Rosswag, S.
Pantel, K.
Sleeman, J. P.
Schmidt, M.
Cotarelo, C. L.
CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 4 5 →